igforum.bio / cedars-sinai-heart-institute-physicians-present-findings-at-american-college-of-cardiology-scientific-meeting - 185194
C
%Begin CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close 18 March 2009 02:00 AM America/Los_Angeles CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING 1 Study Questions the Effectiveness of Routine Aspirin Therapy in Preventing Heart Disease br 2 LVAD May Aid in Weight Loss for Obese Patients Awaiting a Heart Transplant Los Angeles – March 18, 2009 – Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices (LVADs) may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation. These presentations were made at the American College of Cardiology’s Scientific Session in Atlanta.
Charlotte Lee Member
access_time 2 minutes ago
%Begin CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close 18 March 2009 02:00 AM America/Los_Angeles CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING 1 Study Questions the Effectiveness of Routine Aspirin Therapy in Preventing Heart Disease br 2 LVAD May Aid in Weight Loss for Obese Patients Awaiting a Heart Transplant Los Angeles – March 18, 2009 – Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices (LVADs) may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation. These presentations were made at the American College of Cardiology’s Scientific Session in Atlanta.
thumb_up Like (43)
comment Reply (2)
share Share
visibility 439 views
thumb_up 43 likes
comment 2 replies
J
James Smith 1 minutes ago
Brief highlights from these studies are included below. In addition to these presentations, Cedars-S...
C
Christopher Lee 2 minutes ago
The study indicated that aspirin therapy resulted in a minimal reduction in cardiovascular events, b...
T
Brief highlights from these studies are included below. In addition to these presentations, Cedars-Sinai Heart Institute researchers will present findings on gender differences, minimally-invasive surgery, treatments for coronary artery disease and more Does Contemporary Trial Evidence Support the Routine Use of Aspirin in Primary Prevention of Heart Disease? Although current guidelines generally recommend routine use of aspirin for primary prevention of heart disease in men and stroke in women, a meta-analysis of nine trials (104,331 patients) that had evaluated the efficacy of aspirin use in primary prevention of cardiovascular events suggests that aspirin therapy does not result in significant reduction in serious vascular events in either gender.
Thomas Anderson Member
access_time 6 minutes ago
Brief highlights from these studies are included below. In addition to these presentations, Cedars-Sinai Heart Institute researchers will present findings on gender differences, minimally-invasive surgery, treatments for coronary artery disease and more Does Contemporary Trial Evidence Support the Routine Use of Aspirin in Primary Prevention of Heart Disease? Although current guidelines generally recommend routine use of aspirin for primary prevention of heart disease in men and stroke in women, a meta-analysis of nine trials (104,331 patients) that had evaluated the efficacy of aspirin use in primary prevention of cardiovascular events suggests that aspirin therapy does not result in significant reduction in serious vascular events in either gender.
thumb_up Like (3)
comment Reply (2)
thumb_up 3 likes
comment 2 replies
D
David Cohen 5 minutes ago
The study indicated that aspirin therapy resulted in a minimal reduction in cardiovascular events, b...
M
Mia Anderson 4 minutes ago
However, say the authors, there are uncertainties with respect to the drug’s efficacy and ...
S
The study indicated that aspirin therapy resulted in a minimal reduction in cardiovascular events, but it also resulted in a modest increase in bleeding risk. "The results of this study challenge current guidelines regarding aspirin use for cardiovascular disease prevention," said Sanjay Kaul, MD, director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and Allen Research Institute at Cedars-Sinai. Dronedarone: New Atrial Fibrillation Drug Not Recommended as a "First Choice" Recently approved as a therapy for patients with atrial fibrillation/flutter, Dronedarone was specifically designed to overcome the side effects of its parent compound, amiodarone, while effectively reducing arrhythmias.
Sofia Garcia Member
access_time 3 minutes ago
The study indicated that aspirin therapy resulted in a minimal reduction in cardiovascular events, but it also resulted in a modest increase in bleeding risk. "The results of this study challenge current guidelines regarding aspirin use for cardiovascular disease prevention," said Sanjay Kaul, MD, director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and Allen Research Institute at Cedars-Sinai. Dronedarone: New Atrial Fibrillation Drug Not Recommended as a "First Choice" Recently approved as a therapy for patients with atrial fibrillation/flutter, Dronedarone was specifically designed to overcome the side effects of its parent compound, amiodarone, while effectively reducing arrhythmias.
thumb_up Like (10)
comment Reply (2)
thumb_up 10 likes
comment 2 replies
S
Sofia Garcia 1 minutes ago
However, say the authors, there are uncertainties with respect to the drug’s efficacy and ...
A
Audrey Mueller 3 minutes ago
"In general, based on available evidence, it is difficult to support an approach to rhythm ...
C
However, say the authors, there are uncertainties with respect to the drug’s efficacy and safety. In an analysis of several clinical trials thathave evaluated the impact of dronedarone on various cardiovascular end points and yielded mixed results, Cedars-Sinai cardiologists concluded that the available data support the use of dronedarone in select patient populations as a second-or third-line agent, but not as a therapy of first-choice in most patients with atrial fibrillation.
Christopher Lee Member
access_time 8 minutes ago
However, say the authors, there are uncertainties with respect to the drug’s efficacy and safety. In an analysis of several clinical trials thathave evaluated the impact of dronedarone on various cardiovascular end points and yielded mixed results, Cedars-Sinai cardiologists concluded that the available data support the use of dronedarone in select patient populations as a second-or third-line agent, but not as a therapy of first-choice in most patients with atrial fibrillation.
thumb_up Like (38)
comment Reply (0)
thumb_up 38 likes
E
"In general, based on available evidence, it is difficult to support an approach to rhythm control in most patients with atrial fibrillation without first trying a rate-control strategy. More studies with longer follow-up are needed," says senior author Sanjay Kaul, M.D., director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and AllenResearch Institute at Cedars-Sinai.
Ethan Thomas Member
access_time 5 minutes ago
"In general, based on available evidence, it is difficult to support an approach to rhythm control in most patients with atrial fibrillation without first trying a rate-control strategy. More studies with longer follow-up are needed," says senior author Sanjay Kaul, M.D., director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and AllenResearch Institute at Cedars-Sinai.
thumb_up Like (24)
comment Reply (0)
thumb_up 24 likes
C
Implantation of a Ventricular Assist Device may aid in Weight Loss for Obese Patients Awaiting a Heart Transplant For patients who are awaiting a heart transplant, Left Ventricular Assist Devices (LVAD) can literally mean the difference between life and death – helping the patient’s own weakened heart to continue pumping until a suitable donor organ becomes available. In this study, Heart Institute physicians and surgeons note that in addition to assisting the patient’s own heart, LVADs can aid obese heart transplant patients in weight reduction. Weight loss in such patients is important because just as obesity is a risk factor for heart failure, it also is associated with poor outcomes after a heart transplant.
Charlotte Lee Member
access_time 24 minutes ago
Implantation of a Ventricular Assist Device may aid in Weight Loss for Obese Patients Awaiting a Heart Transplant For patients who are awaiting a heart transplant, Left Ventricular Assist Devices (LVAD) can literally mean the difference between life and death – helping the patient’s own weakened heart to continue pumping until a suitable donor organ becomes available. In this study, Heart Institute physicians and surgeons note that in addition to assisting the patient’s own heart, LVADs can aid obese heart transplant patients in weight reduction. Weight loss in such patients is important because just as obesity is a risk factor for heart failure, it also is associated with poor outcomes after a heart transplant.
thumb_up Like (46)
comment Reply (1)
thumb_up 46 likes
comment 1 replies
E
Emma Wilson 24 minutes ago
It is therefore considered a relative contra-indication for transplant. In this analysis of 19 patie...
L
It is therefore considered a relative contra-indication for transplant. In this analysis of 19 patients who were awaiting a transplant, obese advanced heart failure patients lost more weight and reduced their body mass index (BMI) significantly after being implanted with an LVAD. Obese patients who received the device lost about 12 percent of their body weight, nearly double the amount of weight lost by patients who were not obese.
Luna Park Member
access_time 7 minutes ago
It is therefore considered a relative contra-indication for transplant. In this analysis of 19 patients who were awaiting a transplant, obese advanced heart failure patients lost more weight and reduced their body mass index (BMI) significantly after being implanted with an LVAD. Obese patients who received the device lost about 12 percent of their body weight, nearly double the amount of weight lost by patients who were not obese.
thumb_up Like (39)
comment Reply (0)
thumb_up 39 likes
J
According to researchers, the weight loss in patients implanted with the LVAD likely resulted from a combination of factors: the device possibly caused more calories to be consumed while simultaneously also resulting in decreased caloric intake. While the obese patients were previously very sedentary, the LVAD provided more cardiac capacity, thereby enabling these patients to become more active, improve their overall conditioning, and expend more calories.
Jack Thompson Member
access_time 40 minutes ago
According to researchers, the weight loss in patients implanted with the LVAD likely resulted from a combination of factors: the device possibly caused more calories to be consumed while simultaneously also resulting in decreased caloric intake. While the obese patients were previously very sedentary, the LVAD provided more cardiac capacity, thereby enabling these patients to become more active, improve their overall conditioning, and expend more calories.
thumb_up Like (42)
comment Reply (2)
thumb_up 42 likes
comment 2 replies
W
William Brown 25 minutes ago
In addition, the total weight, shape and physical location of the LVAD in the abdomen likely played ...
E
Elijah Patel 10 minutes ago
"LVADs could prove to be helpful in improving obese patients’ outcomes."...
C
In addition, the total weight, shape and physical location of the LVAD in the abdomen likely played a role in reducing caloric intake. "Achieving adequate weight loss appears difficult among obese heart failure patients who are unable to exercise due to de-conditioning and reduced cardiac capacity," said Ernst Schwarz, MD, PhD, director of Multidisciplinary Heart Failure Research at the Cedars-Sinai Heart Institute.
Charlotte Lee Member
access_time 9 minutes ago
In addition, the total weight, shape and physical location of the LVAD in the abdomen likely played a role in reducing caloric intake. "Achieving adequate weight loss appears difficult among obese heart failure patients who are unable to exercise due to de-conditioning and reduced cardiac capacity," said Ernst Schwarz, MD, PhD, director of Multidisciplinary Heart Failure Research at the Cedars-Sinai Heart Institute.
thumb_up Like (16)
comment Reply (3)
thumb_up 16 likes
comment 3 replies
S
Sebastian Silva 8 minutes ago
"LVADs could prove to be helpful in improving obese patients’ outcomes."...
E
Emma Wilson 9 minutes ago
Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics...
Show 1 more replies
E
"LVADs could prove to be helpful in improving obese patients’ outcomes." Share this release CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept. 29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster?
Emma Wilson Admin
access_time 50 minutes ago
"LVADs could prove to be helpful in improving obese patients’ outcomes." Share this release CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept. 29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster?
thumb_up Like (28)
comment Reply (2)
thumb_up 28 likes
comment 2 replies
M
Mia Anderson 41 minutes ago
Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics...
E
Ella Rodriguez 31 minutes ago
CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFI...
S
Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home
Sophia Chen Member
access_time 44 minutes ago
Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home
thumb_up Like (34)
comment Reply (3)
thumb_up 34 likes
comment 3 replies
E
Ethan Thomas 43 minutes ago
CEDARS-SINAI HEART INSTITUTE PHYSICIANS PRESENT FINDINGS AT AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFI...
A
Aria Nguyen 27 minutes ago
Brief highlights from these studies are included below. In addition to these presentations, Cedars-S...
Show 1 more replies

Write a Reply

Similar Discussions